In The News

September 22, 2020
The Food and Drug Administration is expected to spell out a tough new standard for an emergency authorization of a coronavirus vaccine as soon as this week that will make it exceedingly difficult for…
September 22, 2020
Faith in Public Health Guidance, Vaccine, and Treatment Approval Processes Must be Restored to Overcome the Pandemic WASHINGTON, Sept. 22, 2020 /PRNewswire/ -- The Alliance for Aging Research (…
September 22, 2020
Inequities in patient enrollment to cancer clinical trials has once again bubbled to the surface of cancer conversations, resulting in collaboration between clinicians to address and overcome the…
September 21, 2020
Drs. Edith Perez, MD and Lori Pierce, MD discuss the importance of health equity, and the work SU2C and ASCO are doing to increase diversity in cancer research and treatment. “Everyone has the right…
September 10, 2020
In keeping with her Presidential theme of “Equity: Every Patient, Every Day, Everywhere,” in July, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, announced the Society was joining forces with the…
September 9, 2020
On February 4, 2020, the U.S. secretary of health and human services declared that emergency use of diagnostics for SARS-CoV-2 was justified, triggering emergency authority for the Food and Drug…
September 3, 2020
In April, Aetion, the Real World Evidence Platform®, partnered with HealthVerity to launch a real-time treatment tracker for COVID-19, allowing doctors and researchers to assess outcomes and how…
September 2, 2020
CHICAGO, Sept. 2, 2020 /PRNewswire/ -- The Blood Profiling Atlas in Cancer Consortium (BloodPAC) published "Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA…
September 1, 2020
Bristol Myers Squibb awarded a $5 million grant to Stand Up To Cancer for research and education efforts to achieve health equity for underserved patients with lung cancer. The 3-year grant will…
August 28, 2020
NEW YORK – The US Department of Health and Human Services' decision to abruptly restrict the US Food and Drug Administration's ability to require premarket review of laboratory-developed tests (LDTs…